Dear Investors,
I’m pleased to let you know that your June 2026 financial report has now been released.
June was a very strong month for Evergrowth BioHealthcare Capital, and I believe you’ll be pleased with the results.
Historically, biotech stocks tend to trade sideways—or even weaken—during the summer months before beginning a more robust rally in the winter. This year has been different. AbbVie’s recent $10.9 billion acquisition of Apogee Therapeutics sparked a significant resurgence of capital flowing back into the biotech sector, accelerating what is typically a slower season.
As many of you have noticed, several of our largest positions have responded well. Axsome Therapeutics, Erasca, and Grail all posted strong advances during the month, contributing meaningfully to our performance.
As of the end of June:
• 134% gross return since inception
•28% gross return year-to-date (2026)
Looking ahead, I remain optimistic about the sector. Historically, the strongest period for biotech has often occurred during the fall and winter months as investors position themselves ahead of major clinical data releases, regulatory decisions, and increased healthcare conference activity. While no future returns can ever be guaranteed, I continue to believe that owning fundamentally strong biotechnology companies and allowing time for their value to be realized remains one of the most powerful long-term investment strategies.
One interesting milestone I’d like to share: during our first three years since inception, our audited annualized return of 39.1% exceeded the 29.1% annualized return achieved by Warren Buffett during the first three years of Buffett Partnership. While every investment strategy, market environment, and time period is different, I find this comparison both encouraging and motivating. More importantly, we still have six months remaining in 2026, and our focus remains exactly where it has always been—identifying exceptional biotech companies with the potential to create significant long-term value.
Thank you for your continued trust and partnership. I look forward to sharing another strong update with you next month.
To your health, retirement, and superior returns,
Harvey Tran, MD | Chief Investment Officer, Evergrowth BioHealthcare Capital
Join our Skool community page at https://www.skool.com/evergrowthbiohealthcarecapital
Schedule a free consultation with me to see if we are the right fit https://calendly.com/drharveytran/evergrowth-introduction?month=2025-05.
You can check out our Fund Presentation below:
Follow me on Social Media:
Enjoyed This? Stick Around! Subscribe to my newsletter for more insights on using your MD advantage in biotech investing.
Check out our Fund Presentation and our Skool Community Page.